- Home
- SATL vs DERM Comparison
SATL vs DERM Comparison
Compare SATL & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SATL
- DERM
- Stock Information
- Founded
- SATL 2010
- DERM 2014
- Country
- SATL United States
- DERM United States
- Employees
- SATL N/A
- DERM N/A
- Industry
- SATL Radio And Television Broadcasting And Communications Equipment
- DERM Biotechnology: Pharmaceutical Preparations
- Sector
- SATL Technology
- DERM Health Care
- Exchange
- SATL Nasdaq
- DERM Nasdaq
- Market Cap
- SATL 178.8M
- DERM 213.6M
- IPO Year
- SATL N/A
- DERM 2021
- Fundamental
- Price
- SATL $1.47
- DERM $7.67
- Analyst Decision
- SATL
- DERM Strong Buy
- Analyst Count
- SATL 0
- DERM 3
- Target Price
- SATL N/A
- DERM $12.67
- AVG Volume (30 Days)
- SATL 3.3M
- DERM 247.9K
- Earning Date
- SATL 11-10-2025
- DERM 11-12-2025
- Dividend Yield
- SATL N/A
- DERM N/A
- EPS Growth
- SATL N/A
- DERM N/A
- EPS
- SATL N/A
- DERM N/A
- Revenue
- SATL $14,684,000.00
- DERM $59,399,000.00
- Revenue This Year
- SATL N/A
- DERM $26.16
- Revenue Next Year
- SATL N/A
- DERM $45.27
- P/E Ratio
- SATL N/A
- DERM N/A
- Revenue Growth
- SATL N/A
- DERM 2.82
- 52 Week Low
- SATL $1.20
- DERM $3.54
- 52 Week High
- SATL $5.49
- DERM $9.40
- Technical
- Relative Strength Index (RSI)
- SATL 34.22
- DERM 43.69
- Support Level
- SATL $1.26
- DERM $7.27
- Resistance Level
- SATL $1.41
- DERM $8.18
- Average True Range (ATR)
- SATL 0.12
- DERM 0.48
- MACD
- SATL 0.04
- DERM -0.17
- Stochastic Oscillator
- SATL 37.84
- DERM 14.55
About SATL Satellogic Inc.
Satellogic Inc is a provider of satellite imagery to governments and commercial customers globally. It geographically operates in North America, Europe, Asia and South America. It derives maximum revenue from Asia Pacific.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.